Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer

in Endocrine-Related Cancer
Restricted access

Compelling epidemiological evidence shows a strong positive correlation of obesity with thyroid cancer. In vivo studies have provided molecular evidence that high-fat-diet-induced obesity promotes thyroid cancer progression by aberrantly activating leptin-JAK2-STAT3 signaling in a mouse model of thyroid cancer (Thrb PV/PV Pten +/ mice). The Thrb PV/PV Pten +/ mouse expresses a dominantly negative thyroid hormone receptor β (denoted as PV) and a deletion of one single allele of the Pten gene. The Thrb PV/PV Pten +/ mouse spontaneously develops follicular thyroid cancer, which allows its use as a preclinical mouse model to test potential therapeutics. We recently showed that inhibition of STAT3 activity by a specific inhibitor markedly delays thyroid cancer progression in high-fat-diet-induced obese Thrb PV/PV Pten +/ mice (HFD-Thrb PV/PV Pten +/ mice). Further, metformin, a widely used antidiabetic drug, blocks invasion and metastasis, but not thyroid tumor growth in HFD-Thrb PV/PV Pten +/ mice. To improve efficacy in reducing thyroid tumor growth, we treated HFD-Thrb PV/PV Pten +/ with JQ1, a potent inhibitor of the activity of bromodomain and extraterminal domain (BET) and with metformin. We found that the combined treatment synergistically suppressed thyroid tumor growth by attenuating STAT3 and ERK signaling, resulting in decreased anti-apoptotic key regulators such as Mcl-1, Bcl-2 and survivin and increased pro-apoptotic regulators such as Bim, BAD and cleave caspase 3. Furthermore, combined treatment of JQ1 and metformin reduced cMyc protein levels to suppress vascular invasion, anaplasia and lung metastasis. These findings indicate that combined treatment is more effective than metformin alone and suggest a novel treatment modality for obesity-activated thyroid cancer.


      Society for Endocrinology

Article Information


All Time Past Year Past 30 Days
Abstract Views 181 181 96
Full Text Views 802 802 15
PDF Downloads 288 288 7


Related Articles


  • View in gallery

    Effects of metformin, JQ1 and combined treatment on survival and thyroid tumor growth of HFD-Thrb PV/PV Pten +/ mice. (A) Survival curves for HFD-Thrb PV/PV Pten +/ mice treated with vehicle control (open circle, n = 15), metformin (closed circles, n = 11), JQ1 (open square; n = 12) or combination treatment of metformin with JQ1 (closed square, n = 11). Mice were treated high-fat diet (HFD) and metformin (0.5 mg/kg/mouse) from the age of 6 weeks until the age of 20 weeks (the study’s end). JQ1 (50 mg/kg/mouse) was administrated i.p. 5 times a week from age 17 weeks to the end of study (20 weeks). Survival data are shown as a Kaplan–Meier plot and analyzed by log-rank test. The difference in survival was significant between mice between combined treatment and mice treated with vehicle (P = 0.0473), but was not significant between mice treated with vehicle and mice treated with metformin or JQ1. (B) Body weight (panel a) and thyroid weight (panel b) and ratios of thyroid weight to total body weight (panel c) were compared for the mice treated with vehicle, metformin only, JQ1 only and a combination of metformin with JQ1 (n = 9–11). Values are means ± s.e.m. The P values are indicated. NS = not significant.

  • View in gallery

    Metformin, JQ1 and combined treatment inhibit STAT3 and ERK1/2 activation in the thyroid tumors of HFD-Thrb PV/PV Pten +/ mice. (A-I). Western blot analysis for p-STAT3 (Y705) (panel a), total STAT3 (panel b), Mcl-1 (panel c), Bcl-2 (panel d), survivin (panel e) and GAPDH (panel f) in the thyroids of HFD-Thrb PV/PV Pten +/ mice treated with control, metformin, JQ1 or combination treatment, respectively. GAPDH used as a loading control (n = 3–6 for each group). (A-II) The band intensities from western blot analysis detected in (A-I) were quantified by Image J analysis. Ratios of p-STAT3 vs total STAT3 (panel a), Mcl-1 (panel b), Bcl-2 (panel c) and survivin (panel d). All band intensities were normalized using GAPDH as a loading control. Values are shown as means ± s.e.m. The P values are indicated. (B-I) Western blot analysis for p-ERK1/2 (Thr202/Tyr204) (panel a), total ERK1/2 (panel b), Bim (panel c), BAD (panel d) and GAPDH (panel e) in the thyroids of HFD-Thrb PV/PV Pten +/ mice treated with control, metformin, JQ1 or combination treatment, respectively. GAPDH used as a loading control (n = 3–6 for each group). Values are shown as means ± s.e.m. (B-II) The band intensities from western blot analysis detected in (B-I) were quantified by Image J analysis. Ratios of p-ERK1/2 vs total ERK1/2 (panel a), Bim (panel b) and BAD (panel c) are indicated. All band intensities were normalized using GAPDH as a loading control. Values are shown as means ± s.e.m. The P values are indicated. (C-I) Immunohistochemical analysis for cleaved caspase 3 was carried out in the thyroid sections from the control (panel b), metformin (panel d), JQ1 (panel f) and combined treatment (panel h) of HFD-Thrb PV/PV Pten +/ mice. The representative positively stained cells are marked by arrows. The negative control panels using IgG are shown in the corresponding panels (panel a, c, e and g). (C-II) The cleaved caspase 3 positively stained cells were quantified as percentage of cleaved caspase 3-positive cells vs total cells. The P values are indicated.

  • View in gallery

    Combined treatment of metformin and JQ1 synergistically decreases thyroid tumor progression and lung metastasis in HFD-Thrb PV/PV Pten +/ mice. (A-I) The prevalence of hyperplasia (panel a), capsular invasion (panel b), vascular invasion (panel c) and anaplasia (panel d) in the thyroid tumors of HFD-Thrb PV/PV Pten +/ mice treated with vehicle, metformin, JQ1 or combination treatment is shown as percentage of occurrence. *Represents no occurrence (n = 10–16). P values were obtained by Fisher’s exact test. (A-II) Capsular invasion is shown in samples from vehicle (panel a) and metformin treatment alone (panel b) (arrows), but is absent in samples from JQ1 alone (panel c) and combined treatment of JQ1 plus metformin (panel d), showing intact capsules at the margins of tumors (panels c and d). Vascular invasion is demonstrated in vehicle- (panel e) and metformin-treated tumors (panel f) (arrows show tumor cells in vascular lumens). No tumor cells are seen in vascular spaces in JQ1 (panel g) or combined treatment (panel h). Anaplastic foci (arrows) are evident in vehicle (panel i) and metformin-alone treatment (panel j), but no anaplastic foci are seen in JQ1 (panel k) or combined treatment (l). Magnification: panels a–h = ×50; i–l = ×100). (B) The trend in the occurrence of lung metastasis in HFD-Thrb PV/PV Pten +/ mice after treatment with vehicle, metformin, JQ1 and combination treatment is shown (n = 9–11).

  • View in gallery

    Metformin, JQ1 and combination treatment decrease the expression of key regulators of EMT in the thyroid tumors of HFD-Thrb PV/PV Pten +/ mice. (A) Western blot analysis for cMyc (panel a), MMP9 (panel b), vimentin (panel c), N-cadherin (panel d), fibronectin (panel e), E-cadherin (panel g) and GAPDH (panel f and h) in the thyroid tumors of HFD-Thrb PV/PV Pten +/ mice treated with vehicle, metformin, JQ1 and combination treatment. GAPDH used as a loading control (n = 3 for each group). (B) The band intensities from Western blot analysis detected in (A) were quantified by ImageJ analysis. Relative abundance of cMyc (panel a), MMP9 (panel b), vimentin (panel c), N-cadherin (panel d) and fibronectin (panel e), and E-cadherin (panel f) were calculated using the GAPDH as loading control. The P values are indicated.

  • View in gallery

    A proposed model to account for the actions by which metformin and JQ1 together inhibit tumor progression in HFD-Thrb PV/PV Pten +/ mice. HFD induces the aberrant activation of STAT3 and ERK signaling to promote thyroid cancer progression in HFD-Thrb PV/PV Pten +/ mice. JQ1 and metformin together act to increase the tumor cell apoptosis by elevating the protein levels of pro-apoptotic regulators Bim and BAD and by suppressing the protein levels of anti-apoptotic regulators (Mcl1, Bcl2 and survivin), resulting in increased cleaved caspase 3 activity. Combined treatment of JQ1 and metformin also act to suppress invasion and metastasis by decreasing EMT key regulators (cMyc, MMP9, fibronectin, vimentin, N-cadherin) and increasing E-cadherin protein levels. By acting on these two pathways, JQ1 and metformin together suppress obesity-activated thyroid cancer progression. The extent in the thickness of the lines in the inhibition of pSTAT3 and p-ERK signaling schematically represents the degree of suppression.


AlvarezJVFebboPGRamaswamySLodaMRichardsonAFrankDA 2005 Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Research 65 50545062. (

AnisimovVNBersteinLMEgorminPAPiskunovaTSPopovichIGZabezhinskiMAKovalenkoIGPoroshinaTESemenchenkoAVProvincialiMet al. 2005 Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology 40 685693. (

AsanganiIADommetiVLWangXMalikRCieslikMYangREscara-WilkeJWilder-RomansKDhanireddySEngelkeCet al. 2014 Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510 278282. (

Ben SahraILe Marchand-BrustelYTantiJFBostF 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics 9 10921099. (

BhattacharyaSRayRMJohnsonLR 2005 STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochemical Journal 392 335344. (

BlombergMFeldt-RasmussenUAndersenKKKjaerSK 2012 Thyroid cancer in Denmark 1943–2008, before and after iodine supplementation. International Journal of Cancer 131 23602366. (

BorbelyGHaldosenLADahlman-WrightKZhaoC 2015 Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget 6 3362333635. (

CanelMSerrelsAFrameMCBruntonVG 2013 E-cadherin-integrin crosstalk in cancer invasion and metastasis. Journal of Cell Science 126 393401. (

CantrellLAZhouCMendivilAMalloyKMGehrigPABae-JumpVL 2010 Metformin is a potent inhibitor of endometrial cancer cell proliferation – implications for a novel treatment strategy. Gynecologic Oncology 116 9298. (

ChenAYJemalAWardEM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115 38013807. (

ChoKBChoMKLeeWYKangKW 2010 Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Letters 293 230239. (

ChoiJSKimEKMoonHJKwakJY 2015 Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine 48 264271. (

CowlingVHColeMD 2007 E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene 26 35823586. (

CrandallJPKnowlerWCKahnSEMarreroDFlorezJCBrayGAHaffnerSMHoskinMNathanDM & Diabetes Prevention Program Research G 2008 The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology and Metabolism 4 382393. (

DecensiAPuntoniMGoodwinPCazzanigaMGennariABonanniBGandiniS 2010 Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 3 14511461. (

DragutinovicVIzrael-ZivkovicLRadovanovicN 2009 Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Digestive Diseases and Sciences 54 12031207. (

EnomotoKZhuXParkSZhaoLZhuYJWillinghamMCQiJCoplandJAMeltzerPChengSY 2017 Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 102 22682280. (

FilippakopoulosPQiJPicaudSShenYSmithWBFedorovOMorseEMKeatesTHickmanTTFelletarIet al. 2010 Selective inhibition of BET bromodomains. Nature 468 10671073. (

FilippakopoulosPPicaudSMangosMKeatesTLambertJPBarsyte-LovejoyDFelletarIVolkmerRMullerSPawsonTet al. 2012 Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149 214231. (

FuruyaFHanoverJAChengSY 2006 Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. PNAS 103 17801785. (

GaoXWuXZhangXHuaWZhangYMaimaitiYGaoZZhangY 2016 Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochemical and Biophysical Research Communications 469 679685. (

GillingsASBalmannoKWigginsCMJohnsonMCookSJ 2009 Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS Journal 276 60506062. (

GuigonCJZhaoLWillinghamMCChengSY 2009 PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28 509517. (

GuigonCJFozzattiLLuCWillinghamMCChengSY 2010 Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis 31 12841291. (

HanJMKimTYJeonMJYimJHKimWGSongDEHongSJBaeSJKimHKShinMHet al. 2013 Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. European Journal of Endocrinology 168 879886. (

HosonoKEndoHTakahashiHSugiyamaMUchiyamaTSuzukiKNozakiYYonedaKFujitaKYonedaMet al. 2010 Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Molecular Carcinogenesis 49 662671. (

HouPLiuDShanYHuSStudemanKCondourisSWangYTrinkAEl-NaggarAKTalliniGet al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 11611170. (

HouPJiMXingM 2008 Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113 24402447. (

IyerPCDaduRFerrarottoRBusaidyNLHabraMAZafereoMGrossNHessKRGule-MonroeMWilliamsMDet al. 2018 Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28 7987. (

KamranMZPatilPGudeRP 2013 Role of STAT3 in cancer metastasis and translational advances. BioMed Research International 2013 421821.

KimHJKimNKChoiJHSohnSYKimSWJinSMJangHWSuhSMinYKChungJHet al. 2013a Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clinical Endocrinology 78 134140. (

KimWGParkJWWillinghamMCChengSY 2013b Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology 154 29362947. (

KimSAInamuraKYamauchiMNishiharaRMimaKSukawaYLiTYasunariMMorikawaTFitzgeraldKCet al. 2016 Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. British Journal of Cancer 114 199206. (

KitaharaCMPlatzEAFreemanLEHsingAWLinetMSParkYSchairerCSchatzkinAShikanyJMBerrington de GonzalezA 2011 Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiology Biomarkers and Prevention 20 464472. (

KitaharaCMMcCulloughMLFranceschiSRinaldiSWolkANetaGOlov AdamiHAndersonKAndreottiGBeane FreemanLEet al. 2016 Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 26 306318. (

Klubo-GwiezdzinskaJJensenKCostelloJPatelAHoperiaVBauerABurmanKDWartofskyLVaskoV 2012 Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocrine-Related Cancer 19 447456. (

Klubo-GwiezdzinskaJCostelloJJrPatelABauerAJensenKMeteMBurmanKDWartofskyLVaskoV 2013 Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. Journal of Clinical Endocrinology and Metabolism 98 32693279. (

LeeDHQiJBradnerJESaidJWDoanNBForscherCYangHKoefflerHP 2015 Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. International Journal of Cancer 136 20552064. (

LimHDevesaSSSosaJACheckDKitaharaCM 2017 Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317 13381348. (

LockwoodWWZejnullahuKBradnerJEVarmusH 2012 Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. PNAS 109 1940819413. (

LovenJHokeHALinCYLauAOrlandoDAVakocCRBradnerJELeeTIYoungRA 2013 Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 320334. (

LuZXuS 2006 ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58 621631. (

MaJHuangMWangLYeWTongYWangH 2015 Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Medical Science Monitor 21 283291. (

MemmottRMMercadoJRMaierCRKawabataSFoxSDDennisPA 2010 Metformin prevents tobacco carcinogen – induced lung tumorigenesis. Cancer Prevention Research 3 10661076. (

MioCLavaroneEConzattiKBaldanFToffolettoBPuppinCFilettiSDuranteCRussoDOrlacchioAet al. 2016 MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocrine-Related Cancer 23 335347. (

MitaACMitaMMNawrockiSTGilesFJ 2008 Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 14 50005005. (

NotoHGotoATsujimotoTNodaM 2012 Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7 e33411. (

OnderTTGuptaPBManiSAYangJLanderESWeinbergRA 2008 Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research 68 36453654. (

PagetS 1989 The distribution of secondary growths in cancer of the breast 1889. Cancer and Metastasis Reviews 8 98101.

PankovRYamadaKM 2002 Fibronectin at a glance. Journal of Cell Science 115 38613863. (

ParkJKimWGZhaoLEnomotoKWillinghamMChengSY 2016a Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget 7 3483234844.

ParkJWHanCRZhaoLWillinghamMCChengSY 2016b Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. Endocrine-Related Cancer 23 5363. (

PathakKALeslieWDKlonischTCNasonRW 2013 The changing face of thyroid cancer in a population-based cohort. Cancer Medicine 2 537544. (

PierottiMABerrinoFGariboldiMMelaniCMogaveroANegriTPasanisiPPilottiS 2013 Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32 14751487. (

PyoSWHashimotoMKimYSKimCHLeeSHJohnsonKRWheelockMJParkJU 2007 Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. Journal of Cranio-Maxillo-Facial Surgery 35 19. (

RenehanAGTysonMEggerMHellerRFZwahlenM 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 569578. (

RotellaCMMonamiMMannucciE 2006 Metformin beyond diabetes: new life for an old drug. Current Diabetes Reviews 2 307315. (

SatelliALiS 2011 Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Sciences 68 30333046. (

SaxenaNKSharmaDDingXLinSMarraFMerlinDAnaniaFA 2007 Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Research 67 24972507. (

SchmidDRicciCBehrensGLeitzmannMF 2015 Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obesity Reviews 16 10421054. (

ShimamuraTChenZSoucherayMCarreteroJKikuchiETchaichaJHGaoYChengKACohoonTJQiJet al. 2013 Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clinical Cancer Research 19 61836192. (

SubbiahVKreitmanRJWainbergZAChoJYSchellensJHMSoriaJCWenPYZielinskiCCabanillasMEUrbanowitzGet al. 2018 Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. Journal of Clinical Oncology 36 713. (

TakezawaKOkamotoINishioKJannePANakagawaK 2011 Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clinical Cancer Research 17 21402148. (

TsengCH 2014 Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS ONE 9 e109852. (

WangYHouPYuHWangWJiMZhaoSYanSSunXLiuDShiBet al. 2007 High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 92 23872390. (

XingM 2010 Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20 697706. (

YinSCheryanVTXuLRishiAKReddyKB 2017 Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS ONE 12 e0183578. (

ZhuXZhaoLParkJWWillinghamMCChengSY 2014 Synergistic signaling of KRAS and thyroid hormone receptor beta mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia 16 757769. (

ZhuXEnomotoKZhaoLZhuYJWillinghamMCMeltzerPQiJChengSY 2017 Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model. Clinical Cancer Research 23 430440. (

Cited By


Google Scholar